Compare Abeona Therapeutics Inc (ABEO) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fubotv Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Fubotv Inc trades at $9.65 (market cap $290.02M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FUBO | |
|---|---|---|
Market Cap | $373.32M | $290.02M |
Sector | Health | Technology |
52-Week High | $7.23 | $54.72 |
52-Week Low | $4.17 | $8.09 |
Enterprise Value | $228.22M | $460.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FUBO trades at $9.85, down 3.43% today, with a neutral technical signal. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025, representing a significant turnaround to profitability. Recent developments include streaming partnerships with NBCUniversal and the BIG3 basketball league, while analyst consensus remains positive with a $16.25 price target.
FUBO presents a compelling turnaround story with improving profitability metrics and strong analyst support, though negative cash flow and high debt levels pose execution risks. The stock offers substantial upside potential if the company can maintain its path to sustainable profitability through content partnerships and advertising growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
